Kallo Inc. (KALO) Stock Analysis
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Kallo Inc. (KALO) trades at $0.0003. Kallo Inc. develops medical information technology software, including solutions for electronic medical records, disease management, and telehealth. Market cap: $1.91M, Sector: Healthcare.
Price as of Aug 21, 2026 · Last analyzed: Mar 17, 2026Analyst Coverage for KALO: KALO does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates KALO against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
KALO: 1/2 scored disciplines lean bearish. Dominant signal: Seth Klarman bearish.
How is this calculated? →Kallo Inc. (KALO) Healthcare & Pipeline Overview
Kallo Inc. is a healthcare information technology company focused on developing integrated software solutions for electronic medical records, disease management, and telehealth. With a small team and a portfolio of products in development, Kallo aims to enhance healthcare delivery through technology, operating within the competitive healthcare IT sector.
What Is the Investment Thesis for KALO?
Kallo Inc. presents a high-risk, high-reward investment opportunity within the healthcare IT sector. The company's focus on developing integrated medical information technology solutions, including EMR integration and telehealth platforms, addresses a growing need for efficient healthcare data management and remote patient care. However, with a market capitalization of $1.91M and a small team, Kallo faces significant challenges in commercializing its products and competing with established players. The company's beta of 2.70 indicates high volatility. Success hinges on securing funding, achieving regulatory approvals, and successfully marketing its products to healthcare providers. The negative P/E ratio of -0.08 reflects the company's current lack of profitability.
Based on FMP financials and quantitative analysis
KALO Key Highlights
Market capitalization of $1.91M, indicating a micro-cap company with high growth potential but also significant risk.
- Beta of 2.70, reflecting high volatility compared to the overall market.
- Negative P/E ratio of -0.08, signaling that the company is currently not profitable.
- Focus on developing Electronic Medical Records (EMR) Integration Engine, addressing a critical need for interoperability in healthcare.
- Development of KIDS Global Tele-Health Ecosystems, positioning the company to capitalize on the growing telehealth market.
Who Are KALO's Competitors?
KALO is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| CMHSF Comprehensive Healthcare Systems, Inc. | $0.31 | +0.00% | $5.62M | 55 |
| CRBKF Carebook Technologies Inc. | $0.03 | +0.00% | $6.84M | 64 |
| CMPD CompuMed, Inc. | $7.25 | -7.70% | $9.35M | 60 |
| BBLN Babylon Holdings Limited | $0.55 | -13.99% | $14.1M | 56 |
| THKKF Think Research Corporation | $0.23 | -1.74% | $17.8M | 57 |
| AKLI Akili, Inc. | $0.43 | +0.25% | $34.1M | 67 |
| AIRDF Rocket Doctor AI Inc. | $0.44 | -2.99% | $42.4M | 56 |
| VRHI Veri Medtech Holdings Inc. | $2.35 | +0.00% | $46.9M | 67 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are KALO's Key Strengths?
Focus on integrated medical information technology solutions.
- Development of telehealth platforms and mobile clinic technology.
- Proprietary technology such as the KIDS framework.
- Potential for early mover advantage in specialized telehealth segments.
What Are KALO's Weaknesses?
Limited financial resources and small team size.
- Lack of established market presence and brand recognition.
- Dependence on successful commercialization of products in development.
- High beta indicating significant stock volatility.
What Could Drive KALO Stock Higher?
Potential partnerships with healthcare providers to implement Kallo's telehealth solutions.
- Regulatory approvals for Kallo's EMR Integration Engine.
- Increasing adoption of telehealth services due to the COVID-19 pandemic.
- Government initiatives promoting electronic health records and interoperability.
What Are the Key Risks for KALO?
Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
- Limited financial resources to compete with larger healthcare IT companies.
- Failure to achieve market acceptance for Kallo's products.
- Cybersecurity threats and data privacy concerns.
- Rapid technological changes and evolving regulatory requirements.
- High stock volatility due to the company's micro-cap status.
What Are the Growth Opportunities for KALO?
- Expansion of Telehealth Services: The global telehealth market is projected to reach $55.6 billion by 2027, growing at a CAGR of 25.8% from 2020. Kallo's MC-Telehealth and KIDS Global Tele-Health Ecosystems position it to capitalize on this growth by providing virtual medical care and patient education. Success depends on expanding its telehealth platform, securing partnerships with healthcare providers, and demonstrating improved patient outcomes.
- EMR Integration Engine Adoption: The market for EMR systems is expected to grow as healthcare providers seek to improve data interoperability and streamline workflows. Kallo's EMR Integration Engine can address this need by connecting various applications within and outside healthcare facilities. Growth depends on demonstrating the engine's compatibility with different EMR systems, ensuring data security, and offering cost-effective integration solutions.
- Disease Management Solutions: The increasing prevalence of chronic and infectious diseases drives the demand for effective disease management solutions. Kallo's Communicable and Infectious Disease Information Management System can help healthcare providers monitor and manage disease information. Growth depends on expanding the system's capabilities to cover a wider range of diseases, integrating it with public health databases, and providing real-time data analytics.
- Global Market Expansion: Kallo can expand its reach by targeting international markets with its telehealth and EMR integration solutions. The global healthcare IT market is expected to grow, particularly in developing countries with limited access to healthcare services. Success depends on adapting its products to meet local regulatory requirements, establishing partnerships with international healthcare providers, and offering multilingual support.
- Strategic Partnerships: Kallo can accelerate its growth by forming strategic partnerships with established healthcare providers, technology companies, and research institutions. These partnerships can provide access to new markets, funding, and expertise. Potential partners include hospitals, clinics, telehealth providers, and EMR vendors. Success depends on identifying mutually beneficial partnerships, negotiating favorable terms, and integrating its solutions with partner platforms.
What Are KALO's Competitive Advantages?
- Proprietary Technology: Kallo's integrated delivery system (KIDS) and telehealth platform represent unique technological solutions.
- Focus on Integration: The EMR Integration Engine provides a crucial service by connecting disparate healthcare systems.
- Early Mover Advantage: Being an early entrant in specialized telehealth segments can create a competitive edge.
What Does KALO Do?
Kallo Inc., formerly known as Diamond Technologies Inc., was incorporated in 2006 and is headquartered in Toronto, Canada. The company focuses on developing medical information technology software designed to improve healthcare delivery and information management. Kallo's product portfolio includes the Electronic Medical Records (EMR) Integration Engine, which connects various applications within and outside healthcare facilities with the EMR system. Other products in development include the Communicable and Infectious Disease Information Management System, an internet-based solution for monitoring and managing disease information, and Clinical-Care Globalization, a technology aimed at expanding clinical care reach. Kallo also offers MC-Telehealth, a mobile clinic with telehealth system technology, and the Kallo Integrated Delivery System (KIDS), a framework that defines the component parts of its products and services. The KIDS Global Tele-Health Ecosystems is a telehealth program encompassing technologies and administrative processes for delivering virtual medical care, health promotion, and patient education. Kallo's focus is on creating integrated systems to streamline healthcare operations and improve patient outcomes.
What Products and Services Does KALO Offer?
- Develop Electronic Medical Records (EMR) Integration Engine software.
- Create Internet-based solutions for managing communicable and infectious disease information.
- Offer Clinical-Care Globalization technology.
- Provide MC-Telehealth, a mobile clinic with telehealth system technology.
- Develop the Kallo Integrated Delivery System (KIDS) technology and process framework.
- Offer KIDS Global Tele-Health Ecosystems, a telehealth program for virtual medical care and patient education.
How Does KALO Make Money?
- Develops and licenses medical information technology software to healthcare providers.
- Offers telehealth solutions and services to patients and healthcare organizations.
- Generates revenue through software licensing fees, subscription fees, and service fees.
What Industry Does KALO Operate In?
Kallo Inc. operates in the healthcare information services industry, a sector experiencing rapid growth due to the increasing adoption of digital health technologies and the need for efficient data management. The market is driven by factors such as government regulations promoting electronic health records, the rising prevalence of chronic diseases, and the growing demand for remote patient monitoring. Kallo competes with larger, more established players like ACNNF (Accenture), CANB (Can B Corp), CBDNF (CBD of Denver Inc), EPWCF (Empower Clinics Inc), and GABLF (Global Asset Backed Lending LLC), as well as smaller niche providers. Success in this market requires continuous innovation, strong regulatory compliance, and effective marketing to healthcare providers.
Who Are KALO's Key Customers?
- Hospitals and clinics seeking to improve their electronic medical record systems.
- Healthcare providers looking to implement telehealth solutions.
- Public health organizations needing to manage communicable and infectious disease information.
- Patients seeking virtual medical care and health education.
Key Financial Metrics
Return on equity for Kallo Inc. stands at 33.2%, a gauge of how efficiently it converts shareholder capital into profit. Its free cash flow yield is -12.4%, a gauge of the cash the business throws off relative to its market value. A current ratio of 0.00 means current liabilities exceed short-term assets, a liquidity point worth watching.
Kallo Inc. (KALO) Valuation Context
Valued at $1.91M, KALO is classified as a micro-cap stock.
Company Profile
Kallo Inc. operates in the Medical - Healthcare Information Services industry within the Healthcare sector. It is headquartered in Toronto, CA. The company is led by CEO John Cecil. KALO has traded publicly since 2007.
Financial Health
Kallo Inc.'s Piotroski F-Score is 2/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny.
Insider Activity
The most recent 12 insider filings for Kallo Inc. break down as 2 sales and 10 purchases. On net that is roughly 4.6B shares acquired (about $2121.0B) — insiders putting money in tends to read as conviction.
KALO Financials
Bull Case vs Bear Case
Bull Case
- Focus on integrated medical information technology solutions.
- Development of telehealth platforms and mobile clinic technology.
- Proprietary technology such as the KIDS framework.
- Potential for early mover advantage in specialized telehealth segments.
Bear Case
- Limited financial resources and small team size.
- Lack of established market presence and brand recognition.
- Dependence on successful commercialization of products in development.
- High beta indicating significant stock volatility.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · August 2026
KALO Latest News
No recent news available for KALO.
KALO Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for KALO.
Price Targets
Wall Street price target analysis for KALO.
KALO MoonshotScore
What does this score mean?
The MoonshotScore rates KALO 0-100 on quantitative fundamentals — growth, financial health, valuation, momentum, and risk.
Leadership: John Cecil
CEO
John Cecil serves as the CEO of Kallo Inc. His background includes experience in managing small teams and overseeing the development of medical information technology software. He is responsible for the strategic direction and overall management of the company. His expertise lies in identifying opportunities within the healthcare IT sector and guiding the company's product development efforts.
Track Record: Under John Cecil's leadership, Kallo Inc. has focused on developing integrated healthcare solutions, including the EMR Integration Engine and the KIDS Global Tele-Health Ecosystems. Key milestones include the development and ongoing refinement of these core products. His focus has been on positioning the company to capitalize on the growing demand for telehealth and interoperable healthcare systems.
KALO OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that Kallo Inc. may not meet the minimum financial standards or reporting requirements of higher tiers like OTCQX or OTCQB. Companies in this tier may have limited financial disclosure and may be subject to greater risks due to less stringent regulatory oversight. Investing in companies on the OTC Other tier carries a higher degree of risk compared to those listed on major exchanges like NYSE or NASDAQ.
- OTC Tier: OTC Other
- Limited financial disclosure and transparency.
- Higher risk of fraud and manipulation.
- Lower liquidity and wider bid-ask spreads.
- Greater volatility and price fluctuations.
- Potential for delisting or suspension of trading.
- Verify the company's registration and regulatory filings.
- Review the company's financial statements, if available.
- Assess the company's business model and competitive landscape.
- Evaluate the management team's experience and track record.
- Check for any legal or regulatory issues.
- Monitor trading volume and price activity.
- Consult with a financial advisor.
- Company has been in operation since 2006.
- Focus on developing medical information technology software.
- Development of integrated healthcare solutions such as the EMR Integration Engine.
- Presence of a CEO and management team.
What Investors Ask About Kallo Inc. (KALO) — Healthcare
What does Kallo Inc. do?
Kallo Inc. is a healthcare information technology company that develops and markets integrated software solutions for the healthcare industry. Their primary focus is on creating technologies that facilitate the seamless exchange of information between different healthcare systems, improve disease management, and enable telehealth services.
What do analysts say about KALO stock?
As of March 17, 2026, there is no available analyst coverage for Kallo Inc. (KALO). Given its micro-cap status and OTC listing, the company may not attract significant attention from major research firms. Investors should conduct their own thorough due diligence and consider the company's fundamentals, growth prospects, and risk factors before making any investment decisions.
What are the main risks for KALO?
Kallo Inc. faces several significant risks typical of small, developing companies in the healthcare IT sector. These include limited financial resources, intense competition from larger and more established players, the need to navigate complex regulatory requirements, and the potential for rapid technological changes to render their products obsolete.
What are the key factors to evaluate for KALO?
Evaluate KALO on fundamentals, analyst consensus, and risk factors. Kallo Inc. presents a high-risk, high-reward investment opportunity within the healthcare IT sector. Not financial advice.
How frequently does KALO data refresh on this page?
KALO's price was last updated on Aug 21, 2026 and refreshes on page view during U.S. market hours — it is not a real-time exchange feed. Fundamentals update after quarterly filings; the MoonshotScore recalculates nightly; news aggregates continuously.
What has driven KALO's recent stock price performance?
Kallo Inc. (KALO) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Focus on integrated medical information technology solutions. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider KALO overvalued or undervalued right now?
Kallo Inc. (KALO) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
How do I research KALO before investing?
Before investing in Kallo Inc. (KALO), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) analyst consensus ratings and price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on publicly available sources and may be limited due to the company's OTC listing and limited financial disclosure.